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Abstract
Approved in 1989 for the management of treatment-resistant schizophrenia, Clozapine is a last-line atypical antipsychotic
drug used with increasing frequency. In addition to its well-known side effect of agranulocytosis, this drug also carries with
it rare but serious adverse cardiovascular risk of myocarditis. We present a patient on Clozapine who was admitted to the
cardiology service with chest pain, ST segment elevations and elevated troponin concerning for acute myocardial infarction.
Evaluation with imaging revealed decreased left ventricular function, however, no coronary artery disease was present on
catheterization; findings consistent with a diagnosis of myocarditis. Subsequent discontinuation of the patient’s Clozapine
and initiation of brief supportive medical therapy resulted in full recovery of systolic left ventricular function. Given the
potential cardiovascular mortality risk, it is important for physicians on cardiology services caring for psychiatric patients to
be aware of the presentation of symptoms, diagnostic findings and management of Clozapine induced myocarditis.
INTRODUCTION
Clozapine is a last-line atypical antipsychotic agent used to
treat patients with difficult to treat schizophrenia. It is classic-
ally known for its potential serious side effects of agranulocyto-
sis, however also carries a boxed warning for an uncommon,
but important association with adverse cardiovascular effects,
namely myocarditis [1, 2]. In recent reviews, the incidence of
myocarditis associated with Clozapine exposure is 3% [3, 4]. We
report a case of a 40-year-old female started on Clozapine with
subsequent development of myocarditis potentially relating to
this agent. We focus in this vignette on the clinical management
in a cardiac service as well as provide a brief literature review to
understand the possible pathophysiology of Clozapine induced
cardiotoxicity.
CASE REPORT
A 40-year-old transgender male to female with history of schizo-
phrenia initially presenting for suicidal ideation was admitted to
the inpatient psychiatric unit. She was enrolled in the Clozapine
risk evaluation and modification strategy program and started
on the drug 7 days after admission. The medication was up-
titrated to 50mg in the morning and 150mg at night. On Day 9,
she reported chest pain. An EKG demonstrated new marked ST
segment elevations in leads I, avL, II, and V4-V6 (see Figs 1 and
2). Laboratory results revealed elevated troponin of 12 ng/ml
(normal range 0.000–0.034) and creatine kinase MB (CKMB) of
48 ng/ml (normal range 0.00–2.30). Given the EKG findings sug-
gestive of acute ST segment elevation myocardial infarction
(STEMI), she was transferred to our cardiac service.
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On initial evaluation, the patient described substernal chest
pressure. Her past medical history revealed no cardiovascular
disease risk factors. She denied having fevers, chills or upper
respiratory symptoms. Her medication list included Clozapine,
and prior single doses of Hydroxyzine, Haloperidol and
Lorazepam. She took no medications at home. Her vital signs
were stable, cardiac examination was normal. In addition to
elevated troponin and CKMB, labs showed elevated brain natri-
uretic peptide (BNP) of 3070 pg/ml, erythrocyte sedimentation
rate (ESR) of 30mm/h and C-reactive protein (CRP) of 36mg/dl.
An upper respiratory PCR panel was negative for influenza A/B
and other viruses. A urine analysis revealed no signs of infec-
tion. A chest x-ray was unremarkable.
The patient was taken immediately to the catheterization
lab and no occlusive coronary artery disease was seen. A trans-
thoracic echocardiogram revealed ejection fraction of 30–35%
with moderate global hypokinesis. Given high suspicion for
drug induced myocarditis, Clozapine was stopped. The patient
Figure 1: EKG prior to Clozapine initiation.
Figure 2: EKG during chest pain event after Clozapine therapy.
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was monitored on telemetry and started on cardiac medical
management with low doses of Metoprolol (12.5mg twice a
day) and Lisinopril (2.5mg daily).
She remained chest pain free through the remainder of her
course without development of shortness of breath, orthopnea
or lower extremity swelling. On hospital Day 20 (4 days after
discontinuation of Clozapine) a repeat transthoracic echocar-
diogram showed fully recovered left ventricular function with
an ejection fraction of 65% and no wall motion abnormalities.
Timeline of Events is shown in Fig. 3. Cardiac medications
were discontinued and ventricular function remained recov-
ered. The patient was transferred back to the psychiatry
inpatient team in stable condition for further management of
her schizophrenia.
DISCUSSION
Development of myocarditis as a result of Clozapine therapy
generally occurs within the first 2–8 weeks of therapy [5]. At
time of diagnosis, the mean age of patients has been reported
as 33.5 years with mean dose of Clozapine 360mg [6]. Rule out
of other etiologies of myocarditis/inflammatory cardiomyop-
athy with testing for viral respiratory infection, autoimmune
diseases and giant cell myocarditis is imperative [7–9].
Laboratory testing to look for myocardial damage with elevated
cardiac enzymes as well as evaluation of electrocardiogram
and chest x-ray are standard measures. In our case, the diffuse
ST segment elevations on electrocardiogram are seen with peri-
carditis however taking the entire clinical picture into context,
myocarditis remained the leading diagnosis. Supportive evi-
dence additionally includes elevated BNP and absence of hyper-
tension or history of valvular disease. Echocardiogram to
assess ventricular function and provide confirmation of devel-
oping ventricular failure is also helpful [5]. In the presence of
reduced systolic function, a cardiac catheterization to confirm
lack of obstructive or ischemic coronary disease further con-
firms a diagnosis of myocarditis. The role of re-challenging a
patient with Clozapine after myocarditis is controversial. While
there have been mixed results, there are not enough cases with
rechallenge reported to draw definitive conclusions. The deci-
sion depends upon patient discussion to weigh quality of life
without Clozapine therapy versus risk of myocarditis on rechal-
lenge. We did not rechallenge our patient. A major limitation in
our diagnosis was the inability to obtain cardiac magnetic res-
onance imaging. In the absence of endomyocardial biopsy, this
modality is important. Lastly, we could not confirm that the
patient was not abusing any other substances no longer avail-
able once admitted, contributing to functional recovery.
Management of clozapine myocarditis is supportive and
empiric [6]. Once the diagnosis is established, if drug induced
myocarditis is suspected, the inciting agent should be discon-
tinued immediately. Administration of diuretics, beta blockers
and angiotensin converting enzyme inhibitors have been
shown to support myocardial function during the acute myo-
cardial insult [5]. Trending levels of inflammatory markers such
as ESR and CRP have been suggested as ways to document
recovery [10].
Discontinuation of Clozapine leads to cardiac functional
recovery with a direct correlation in degree of compromised
systolic function to degree of recovery, however mortality is
still 12.5–24% [4, 6, 11]. The timeline of onset of cardiac func-
tional recovery from the time of discontinuation of drug is vari-
able. Discontinuation of Clozapine should be done with close
liason with Psychiatry colleagues as relapse of Schizophrenia
may ensue leading to significant patient harm.
The mechanism of Clozapine induced myocarditis has not
been well established. Links with geographical region based on
ozone concentrations, genetic predisposition, Ig E mediated
hypersensitivity and elemental deficiencies have been pro-
posed. In a review conducted of 47 cases of Clozapine induced
myocarditis, the development of eosinophilia suggesting IgE
mediated hypersensitivity reaction has been documented in
~66% of cases [10]. The highest rates of Clozapine induced car-
diomyopathy have been reported in New Zealand and Australia
Figure 3: Timeline of events.
Clozapine-induced myocarditis | 13
Downloaded from https://academic.oup.com/omcr/article-abstract/2018/1/omx080/4794785
by Gelman Library - George Washington University user
on 16 January 2018
possibly due to possibly increased blockade of M2 receptors
and cholinergic receptor dysfunction in these areas of higher
ozone concentrations [12]. Genetic predisposition is thought to
be mediated by mutations in pharmacokinetic enzymes
CYP450-1A2 and CY450-1A3 [6].
To further consider is inherent alpha-adrenergic blocking
effects of antipsychotics [4]. This is supported by the fact that
patients prescribed Clozapine are those exposed to many anti-
psychotics before initiation of this last line agent suggesting
some degree of cumulative effect.
The role of sophisticated monitoring systems dedicated to
detecting cardiovascular complications associated with cloza-
pine has been established. Protocols focus mainly on keeping a
high index of suspicion for early recognition of symptoms [13].
Ongoing discussions remain to include cardiac markers in
weekly blood work along with markers of inflammation in
these protocols.
In summary, our case highlights a rare yet potentially fatal
cardiovascular complication potentially relating to Clozapine
use. Recent cohort studies have shown that myocarditis and
sudden cardiac death are uncommon in patients maintained
on clozapine however given the fatal clinical significance, pre-
ventive measures need to be further studied [14]. Given lethal
risk and boxed warning for cardiovascular toxicity, chest dis-
comfort in a patient commencing Clozapine should be investi-
gated for a symptom of myocarditis.
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